Intraoperative fentanyl in endoscopic procedures and their impact on PACU time and costs
- PMID: 40114263
- PMCID: PMC11924838
- DOI: 10.1186/s13741-025-00515-x
Intraoperative fentanyl in endoscopic procedures and their impact on PACU time and costs
Abstract
Background: Extended stays in the postanesthesia care unit (PACU) pose challenges in high-volume endoscopies. This study investigates the impact of intraoperative fentanyl use on PACU duration, postoperative pain, and financial implications in outpatient endoscopy.
Method: A retrospective analysis of upper/lower endoscopies at our facility (2020-2022) was conducted, focusing on the relationship between fentanyl use, PACU duration, and pain scales. Financial impacts were also assessed.
Results: Among 11,488 patients, 5787 (50.4%) received intraoperative fentanyl, and 5225 (45.5%) had a long stay at PACU (> 50 min). A larger proportion of patients in the long-stay group (> 50 min) received fentanyl (56.3% vs. 45.4%, P < 0.01), and they reported higher Numeric Rating Scale (NRS) pain scores (> 5 in 3.6% vs. 1.2%, P < 0.01). The median PACU time was longer for fentanyl recipients (52 vs. 48 min, P < 0.01). Multivariable analysis identified fentanyl use, older age, and higher ASA scores (≥ 3) as significant factors for prolonged PACU durations. Fentanyl did not significantly reduce postoperative pain (scores > 5: 2.8% for fentanyl users vs. 2.2% for nonusers). Furthermore, most patients reported no pain post-surgery (93.0% for fentanyl users vs. 95.2% for nonusers). Fentanyl recipients did not have shorter PACU stays within any pain scale category. Financial simulations suggest that fentanyl-free anesthesia management could notably decrease the financial burden within endoscopy operations. Specifically, our institution could have realized an annual saving of at least US $100,308.
Conclusion: Intraoperative fentanyl increases PACU duration by approximately 4 min per patient in endoscopies, without markedly improving pain management. Avoiding fentanyl could lead to significant time and cost savings.
Keywords: Anesthesiology; Endoscopy; Fentanyl; Pain; Postanesthesia care unit (PACU).
© 2025. This is a U.S. Government work and not under copyright protection in the US; foreign copyright protection may apply.
Conflict of interest statement
Declarations. Ethics approval and consent to participate: Institutional Review Board (protocol number is 72022). Consent for publication: I confirm that I understand Perioperative Medicine is an open-access journal that levies an article processing charge per articles accepted for publication. By submitting my article, I agree to pay this charge in full if my article is accepted for publication. Competing interests: S.B. is a consultant for Boston Scientific.
Figures
References
-
- Angst MS, Koppert W, Pahl I, Clark DJ, Schmelz M. Short-term infusion of the μ-opioid agonist remifentanil in humans causes hyperalgesia during withdrawal. Pain. 2003;106(1):49–57. 10.1016/S0304-3959(03)00276-8. - PubMed
-
- Beaussier M, Decorps A, Tilleul P, Megnigbeto A, Balladur P, Lienhart A. Desflurane improves the throughput of patients in the PACU. A cost-effectiveness comparison with isoflurane. Can J Anesth Can Anesth. 2002;49(4):339–346. 10.1007/BF03017320 - PubMed
-
- Bell A, Andrews C, Highland KB, Senese FA. Opioid-free anesthesia in the perioperative setting—a preliminary retrospective matched cohort study. Mil Med. 2022;187(3–4):e290–6. 10.1093/milmed/usaa570. - PubMed
-
- Bhat UN. An introduction to queueing theory: modeling and analysis in applications. Springer; 2008.
LinkOut - more resources
Full Text Sources